FarmaKology Newsletter - Issue #54
Capio Biosciences is a biotech start-up focused on delivering high-value oncology diagnostics that can help inform patient care decisions and improve outcomes. At Capio Biosciences we are currently developing an advanced platform called CapioCyte™ for the capture of circulating tumor cells (CTCs) from whole blood. By utilizing a combination of biomimetic cell rolling and dendrimer-mediated multivalent cell capture, CapioCyte delivers significantly greater capture sensitivity than other platforms currently available. It is also able to provide enriched CTCs for post capture molecular analysis such as FISH, RNA-Seq and NGS. CapioCyte is therefore an excellent tool for today’s cancer research needs, and potentially for clinical patient management in the future.
Trials for the potential treatment of Covid-19 are being accelerated, with the third and final phase for the drug due to start in a few weeks' time.Developed by Singapore-based biotechnology company Tychan, the monoclonal antibody - or immune system protein is known as TY027 - will be tested on 500 recently diagnosed Covid-19 patients.
Biogen strikes $1 billion deal with Denali to advance Parkinson’s drug based on approach that was nearly abandoned
Biogen Inc. and Denali Therapeutics Inc., today announced that they have signed a binding agreement to co-develop and co-commercialize Denali’s small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson’s disease. Biogen will also receive rights to opt into two programs and a right of first negotiation for two additional programs, in each case for neurodegenerative diseases leveraging Denali’s Transport Vehicle technology platform to cross the blood-brain barrier .
Novartis receives EC approval for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps
Novartis today announced that the European Commission has approved Xolair® (omalizumab) as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) for whom therapy with INC does not provide adequate disease control 1. Phase III studies have shown that Xolair reduces nasal polyp size and improves symptoms and quality of life in patients with CRSwNP5. Xolair is the first treatment for CRSwNP specifically targeting and blocking immunoglobulin E (IgE), a key driver in the inflammatory pathway of this disease.
FDA approves GSK’s BLENREP (belantamab mafodotin-blmf) for the treatment of patients with relapsed or refractory multiple myeloma
GlaxoSmithKline announced the US Food and Drug Administration has approved BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunomodulatory agent. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. BLENREP is the first anti-BCMA (B-cell maturation antigen) therapy approved anywhere in the world.
Research & Study
Listen to Mad Scientists Revive 100-Million-Year-Old Microbes and twenty-nine more episodes by WIRED Science: Space, Health, Biotech, And More, free! No signup or install needed. Mad Scientists Revive 100-Million-Year-Old Microbes. These 4 Covid-19 Vaccines Are Closest to Becoming Reality.